AstraZeneca’s Admission on Vaccine Side Effects: Implications for India’s Health Policy

AstraZeneca has recently admitted in a UK court that its COVID-19 vaccine, developed in collaboration with Oxford University, can cause Thrombosis with Thrombocytopenia Syndrome (TTS) in "very rare cases." This admission is particularly significant for India, where the vaccine was manufactured by the Serum Institute of India and marketed as Covishield, forming the backbone of the national immunization drive by accounting for over 80% of the doses administered. TTS is a rare condition characterized by blood clots (thrombosis) occurring in conjunction with a low platelet count (thrombocytopenia). While global health organizations, including the WHO, have consistently maintained that the benefits of the vaccine in preventing severe COVID-19 far outweigh the risks, this legal admission brings critical focus to the safety protocols and legal accountability of pharmaceutical companies during public health emergencies.